Comparative Cancer Risk in Patients With Psoriasis Treated With Adalimumab, Secukinumab, or Ustekinumab.
- DOI
- 10.1001/jamadermatol.2025.3928
- Published
- 2025 Dec 1
- Container
- JAMA dermatology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1001/jamadermatol.2025.3928,
title = {Comparative Cancer Risk in Patients With Psoriasis Treated With Adalimumab, Secukinumab, or Ustekinumab.},
author = {Schwarz CW and Rasmussen MK and Bertelsen T and Iversen L and Skov L and Loft N},
year = {2025},
journal = {JAMA dermatology},
doi = {10.1001/jamadermatol.2025.3928},
url = {https://doi.org/10.1001/jamadermatol.2025.3928}
}RIS
TY - JOUR TI - Comparative Cancer Risk in Patients With Psoriasis Treated With Adalimumab, Secukinumab, or Ustekinumab. AU - Schwarz CW AU - Rasmussen MK AU - Bertelsen T AU - Iversen L AU - Skov L AU - Loft N PY - 2025 JO - JAMA dermatology DO - 10.1001/jamadermatol.2025.3928 UR - https://doi.org/10.1001/jamadermatol.2025.3928 ER -
APA
CW, S., MK, R., T, B., L, I., L, S., & N, L. (2025). Comparative Cancer Risk in Patients With Psoriasis Treated With Adalimumab, Secukinumab, or Ustekinumab.. JAMA dermatology. https://doi.org/10.1001/jamadermatol.2025.3928
Source records
- pubmed · retrieved 2026-09-26T09:37:29.738Z